The emergence of artemisinin partial resistance in Africa: how do we respond?

Malaria, a major infectious disease, is primarily caused by Plasmodium falciparum infection in sub-Saharan Africa. ART-R, the most important class for treatment, has risen in eastern Africa due to single point mutations in the P falciparum kelch13 protein. Major priorities include expanding genomic surveillance for ART-R mutations, testing artemisinin-based regimens against uncomplicated and severe malaria, assessing ex-vivo drug susceptibilities, considering changes in treatment policy to deter ART-R spread, and accelerating the development of new antimalarial regimens to overcome its impacts. The emergence of ART-R in Africa is an urgent concern, necessitating increased efforts to characterize its spread and mitigate its impact.